Related Experiment Videos

Cefoperazone for urethritis due to penicillinase-producing Neisseria gonorrhoeae

Clinical Therapeutics
|January 1, 1984
PubMed

Insights

Cefoperazone effectively treated most men with penicillinase-producing Neisseria gonorrhoeae infections. However, a notable percentage experienced treatment failure or developed postgonococcal urethritis, indicating potential challenges with this antibiotic regimen.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Penicillinase-producing Neisseria gonorrhoeae (PPNG) poses a significant challenge in gonorrhea treatment.
  • Antimicrobial resistance in Neisseria gonorrhoeae necessitates the evaluation of alternative therapeutic agents.

Purpose of the Study:

  • To assess the efficacy and clinical outcomes of cefoperazone in treating men with PPNG infections.
  • To determine the cure rates and incidence of postgonococcal urethritis following cefoperazone administration.

Main Methods:

  • A clinical study involving 32 men diagnosed with PPNG infection.
  • Treatment administered as a single intramuscular dose of 0.5 gm of cefoperazone.
  • Follow-up assessments conducted on 29 patients to evaluate treatment outcomes and complications.

Main Results:

  • A high cure rate of 93% was observed among the 29 followed-up patients.
  • Seven patients (26%) developed postgonococcal urethritis post-treatment.
  • Minimum Inhibitory Concentrations (MICs) of cefoperazone ranged from 0.03 to 0.5 microgram/ml across different strains.

Conclusions:

  • Cefoperazone demonstrates significant efficacy in treating most cases of PPNG infections.
  • The occurrence of postgonococcal urethritis warrants further investigation and consideration in treatment protocols.
  • Cefoperazone represents a viable therapeutic option for PPNG, though monitoring for adverse outcomes is crucial.

Related Concept Videos